Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus.

18 Jun 2021

Landmark multiple myeloma study completes enrolment and method development

Binding Site is pleased to announce that the ground-breaking iStopMM study has reached an important milestone.

From Binding Site 17 Jun 2021

UC San Diego Health offers new immunotherapy treatment for multiple myeloma following FDA approval

Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.

3 Jun 2021

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

Could the marine compound plitidepsin promote recovery from moderate COVID-19?

A new paper by an international team of researchers describes experimental evidence of the antiviral efficacy of a marine compound called plitidepsin against SARS-CoV-2. The findings show that plitidepsin inhibits SARS-CoV at low concentrations, as observed by a thousand-fold reduction in genomic RNA and viral titers in cells exposed to the virus in culture when treated.

27 May 2021

Decreasing activity of ZMPSTE24 protease with age and comorbidities may make elderly COVID-19 patients vulnerable

Studies have shown that circulating levels of PAI-1, the coagulation cascade activator, are considerably higher in COVID-19 patients with severe respiratory illness compared to patients with bacterial-sepsis and acute respiratory distress syndrome (ARDS). Hence the increase in PAI-1 levels is recognized as an early marker of endothelial dysfunction in COVID-19 patients.

23 May 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

17 Apr 2021

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.

2 Apr 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

New blood test makes it easier to follow the progression of multiple myeloma

A new method makes it much easier to follow the progression of multiple myeloma, a form of blood cancer.

26 Mar 2021

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Bariatric surgery can significantly reduce the risk of cancer--and especially obesity-related cancers--by as much as half in certain individuals, according to a study by researchers at Rutgers Robert Wood Johnson Medical School's Center for Liver Diseases and Liver Masses.

26 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Underrepresentation in genomic databases may affect therapy selection for minority patients

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

19 Mar 2021

Novel cancer-fighting gene therapy enters phase I clinical trial

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells.

18 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.

2 Mar 2021

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

Landmark multiple myeloma study completes enrolment and method development

UC San Diego Health offers new immunotherapy treatment for multiple myeloma following FDA approval

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Could the marine compound plitidepsin promote recovery from moderate COVID-19?

Decreasing activity of ZMPSTE24 protease with age and comorbidities may make elderly COVID-19 patients vulnerable

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

First cell-based gene therapy approved by the FDA for treating multiple myeloma

New blood test makes it easier to follow the progression of multiple myeloma

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Underrepresentation in genomic databases may affect therapy selection for minority patients

Novel cancer-fighting gene therapy enters phase I clinical trial

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Immunomodulatory drugs improve the success rate of cancer therapies

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in